Questions About iPS Cells

In his blog, CIRM grantee Paul Knoepfler at UC Davis posted a response to the journal Stem Cells, which had published a list of the most pressing questions about iPS cells:

“What I found most striking is that not one of their 10 questions had anything to do with safety or tumorigenicity, the question I rank #1, but otherwise my top 5 most important questions about IPS cells are similar to theirs. I know they think safety is a crucial issue, which is why I’m so surprised it wasn’t on their list.”

Knoepfler’s focus on tumorigenicity stems from his lab’s work, which he discusses in this video about the safety of stem cell-based therapies (embryonic or iPS).

Knoepfler is taking suggestions for additional top 5 lists.